Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 11Leukemia, Myeloid, Acute 10Lung Neoplasms 9Myelodysplastic Syndromes 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Non-Small-Cell Lung 5Leukemia, Biphenotypic, Acute 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Osteosarcoma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Mycosis Fungoides 2Melanoma 2

Interventions

canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clonal Cytopenia of Undetermined Significance × X-Rays × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡